Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE achieves milestone in drug development against Alzheimer’s and other age-related diseases: new compounds discovered through self-developed AI Virtual Screen with Recommendation Success Rate 40 times higher than traditional Screening Methods
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Miscellaneous
Aladdin Healthcare Technologies SE achieves milestone in drug development against Alzheimer’s and other age-related diseases: new compounds discovered through self-developed AI Virtual Screen with Recommendation Success Rate 40 times higher than traditional Screening Methods The life journey of a drug can last up to ten years before arriving on the market and it is marked by rigorous and cost-intensive tests. Aladdin can offer a high-quality prediction of drug-target interactions and accelerate the discovery process of new compounds thanks to its proprietary AI Drug Development platform, which uses an implemented virtual screening system and a huge dynamic database, reducing the usual preclinical phase time of drug development from two to three years to only 12 months. Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE, comments: “The co-development of these new compounds marks a new era, where drug targets can be identified faster and optimized, by combining medical expertise with Artificial Intelligence. Our self-developed AI Drug Discovery platform AIDD can contribute to the worldwide scientific progress and improve the health conditions of patients affected by age-related and neurodegenerative diseases, like Alzheimer’s Disease.” Aladdin keeps up the pace of new findings and continues to work with major international partners in the field of medical research. Only last week the Company announced another relevant discovery of 20 novel compounds to fight against the coronavirus and COVID-19. By reducing the time needed for the pre-clinical phase within the drug development process and finding new potential optimized treatments for complex diseases, Aladdin confirms its capability of making exciting progress and heading to important partnerships with big players in the pharma industry and major profitable contracts. About Aladdin Healthcare Technologies SE Website Link: www.aladdinid.com For further information Contact Press
28.05.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English |
Company: | Aladdin Healthcare Technologies SE |
Unter den Linden 10 | |
10117 Berlin | |
Germany | |
Phone: | 030 700140449 |
E-mail: | info@aladdinid.com |
Internet: | www.aladdinid.com |
ISIN: | DE000A12ULL2 |
WKN: | A12ULL |
Listed: | Regulated Market in Dusseldorf |
EQS News ID: | 1057639 |
End of News | DGAP News Service |